Targeted gene silencing in vivo by platelet membrane-coated metal–organic framework nanoparticles

Summary

This preclinical study tackles several barriers to therapeutic small interfering RNA: efficient loading, escape from endosomes, and delivery to diseased tissue in vivo. The researchers encapsulated siRNA in a pH-sensitive metal–organic framework core, which provided high loading and was designed to disrupt endosomes after cellular uptake. A platelet-membrane coating supplied a natural biological interface with affinity for disease substrates. In vitro experiments achieved strong silencing against multiple target genes, indicating that the system could deliver functional siRNA rather than merely internalize it. In a mouse xenograft model, the coated particles showed substantial tumor targeting and produced therapeutic benefit. The principal finding is that the MOF core and platelet surface solve complementary stages of the delivery problem: the membrane supports tissue interaction, while the core packages siRNA and enables intracellular release. Its significance is an integrated biomimetic platform that could extend RNA interference to disease settings where naked siRNA is unstable or poorly localized. The abstract does not name the genes, tumor type, silencing magnitude, dosing, comparison carriers, off-target effects, immune responses, or durability, so it supports a broad proof of concept rather than a clinically defined therapy.